Predictive biomarker for cancer treatment with ADCC-enhanced antibodies
AssigneeRoche Glycart AG
InventorsLilla Di Scala, Stefan Evers, Christian Gerdes, Christoph Mancao, Alexandre Passioukov, Pablo Umana
Life of this patent
Estimating the term…
Abstract
The present invention is directed to methods for identifying which patients diagnosed with cancer will most benefit from treatment with an anti-cancer therapy comprising an ADCC-enhanced antibody.
Claims18
A method of predicting the response of a cancer patient to treatment with an ADCC-enhanced antibody, comprising determining the level of CD3+ and CD16+ cell infiltration in the tumor of the patient prior to treatment and comparing said level of CD3+ and CD16+ cell infiltration to a reference level, wherein a higher level of CD3+ and CD16+ cell infiltration compared to the reference level is indicative for a patient who will derive clinical benefit from the treatment.
A method for the treatment of cancer in a patient, wherein i) the level of CD3+ and CD16+ cell infiltration in the tumor of the patient is determined prior to treatment, and ii) an ADCC-enhanced antibody is administered to a patient if the level of CD3+ and CD16+ cell infiltration in the tumor of the patient is higher than a reference level.
Dependencies are inferred from the claim text.